An open-label phase II study of the efficacy of combination bortezomib-containing regimens in the treatment of newly diagnosed patients with t (4; 14) positive multiple myeloma.

Trial Profile

An open-label phase II study of the efficacy of combination bortezomib-containing regimens in the treatment of newly diagnosed patients with t (4; 14) positive multiple myeloma.

Completed
Phase of Trial: Phase II

Latest Information Update: 05 Dec 2016

At a glance

  • Drugs Bortezomib (Primary) ; Cyclophosphamide; Dexamethasone; Doxorubicin liposomal; Prednisone
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Dec 2016 Status changed from active, no longer recruiting to completed.
    • 07 Mar 2016 Planned End Date changed from 1 Dec 2015 to 1 Sep 2016 as reported by ClinicalTrials.gov.
    • 15 Oct 2015 Planned End Date changed from 1 Jul 2015 to 1 Dec 2015, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top